MDNA Medicenna Therapeutics Corp
- 2.340
- -0.150-6.02%
Medicenna Therapeutics Corp News
Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum
Medicenna Provides Update on Its Presentations at the 2024 ASCO Annual Meeting
Medicenna Therapeutics Announces Closing of CA$20 Million Investment From RA Capital Management
Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 30, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" o
Canadian Investment Regulatory Organization Trading Halt - MDNA
Medicenna Therapeutics Announces CA$20 Million Investment From RA Capital Management
Medicenna Therapeutics Up 13% After Flagging Presentations
Medicenna Therapeutics (MDNA.TO) was up near 13% on Wednesday after saying it will be presenting two abstracts, including an oral podium presentation, at the Annual Meeting of the American Society of
Medicenna Announces Oral Presentation of MDNA11 Data From the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
Oral presentation of MDNA11's Phase 1/2 ABILITY-1 Study will feature new and updated clinical data Updated bizaxofusp survival results from the Phase 2b recurrent glioblastoma trial versus propensity
Medicenna Therapeutics Presents Separate Updated Results and Preclinical Data; Shares Lost Near 12% Today
Medicenna Therapeutics (MDNA.TO), a clinical-stage immunotherapy company focused on the development of Superkines that saw its shares drop near 12% today, after trade Tuesday said it presented updated
Medicenna Brief: Comes After Its Shares Lost Near 12% Today; Earlier Today Said Presented Updated Preclinical Data On MDNA113, A First-In-Class, Targeted And Masked Bi-Functional Anti-PD1-IL2 Superkine
04:32 PM EDT, 04/09/2024 (MT Newswires) -- Medicenna Brief: Comes After Its Shares Lost Near 12% today; Earlier Today Said Presented Updated Preclinical Data On MDNA113, A First-In-Class, Targeted And
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity From Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Medicenna Therapeutics presented updated clinical results from the monotherapy dose escalation and ongoing expansion portions of the Phase 1/2 ABILITY-1 (A Beta-only IL-2 ImmunoTherapY) study evaluating MDNA11.
Medicenna Therapeutics Down 11% as It Presents Updated Preclinical Data on MDNA113 at AACR 2024
Medicenna Therapeutics (MDNA.TO) was down 11% on last look, after the company on Tuesday after new preclinical data on MDNA113, its T-MASK (Targeted Metallo/protease Activated SuperKine) candidate, wa
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional Anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Medicenna Therapeutics Corp. (TSX: MDNA) today announced new preclinical data on MDNA113, the Company's novel T-MASK (Targeted Metallo/protease Activated SuperKine) candidate, an IL-13R⍺2 (Interleukin-13 receptor alpha2) specific superkine featuring unique masking and tumor targeting characteristics, were presented at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) held in San Diego, CA, on April 9th, 2024.
Stocks in Play: Medicenna Therapeutics Corp
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
Medicenna Reports Q3 Net Loss $5.0 Million
Medicenna Therapeutics Corp. (MDNA.TO), a clinical-stage immunotherapy company focused on the development of Superkines, on Wednesday reported that net loss for the quarter ended December 31, 2023, wa
Medicenna Brief: Net Loss for the Quarter Ended December 31, 2023, Was $5.0 Million or ($0.07) per Share Compared to a Net Loss of $1.1 Million or ($0.02) per Share for the Quarter Ended December 31, 2022
07:31 AM EST, 02/14/2024 (MT Newswires) -- Medicenna Brief: Net loss for the quarter ended December 31, 2023, was $5.0 million or ($0.07) per share compared to a net loss of $1.1 million or ($0.02) pe
Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update
Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination With KEYTRUDA (Pembrolizumab) in Patients With Advanced Solid Tumors
Medicenna Announces Appointment of New Auditor
TORONTO and HOUSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused on the deve
Stocks in Play: Medicenna Therapeutics Corp.
